Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Trading Down 5.6% – Time to Sell?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s share price was down 5.6% during trading on Tuesday . The stock traded as low as $38.43 and last traded at $38.8350. Approximately 146,275 shares were traded during trading, a decline of 76% from the average daily volume of 612,458 shares. The stock had previously closed at $41.12.

Analyst Ratings Changes

Several equities analysts have issued reports on KNSA shares. TD Cowen assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average price target of $52.33.

Kiniksa Pharmaceuticals International Stock Down 6.2%

The business’s fifty day moving average is $41.33 and its 200-day moving average is $36.50. The company has a market cap of $2.92 billion, a PE ratio of 85.72 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same period in the prior year, the company posted ($0.18) earnings per share. The firm’s quarterly revenue was up 61.2% on a year-over-year basis. Analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $41.89, for a total transaction of $502,680.00. Following the completion of the transaction, the chief financial officer directly owned 19,086 shares in the company, valued at approximately $799,512.54. The trade was a 38.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 510,689 shares of company stock worth $20,009,290 over the last three months. 53.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter worth $31,000. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth $32,000. Quantbot Technologies LP bought a new stake in Kiniksa Pharmaceuticals International during the second quarter valued at about $43,000. Finally, Quarry LP purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter valued at about $44,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.